Drug intelligence / Profile preview

Enzystream

Development stage: Unknown
Lead developer: EnzySurge
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

**Enzystream** is a topical enzymatic debridement solution containing papain, a proteolytic enzyme derived from papaya, used in the DERMASTREAM™ - ENZYSTREAM™ system for wound care. It facilitates the removal of non-viable tissue, bacteria, and debris from chronic wounds such as venous leg ulcers by selectively breaking down necrotic material through cysteine protease activity, promoting cleaner wound beds for healing. Developed by EnzySurge, it was evaluated in a phase 1/2 clinical trial (NCT00485329, completed) at low (15,000 USP U/ml), medium (30,000 USP U/ml), and high (60,000 USP U/ml) doses, administered via a delivery system, with a 4:1 drug-to-placebo ratio per arm.[3][7]

Brand names: Enzystream

Targets

Necrotic tissue proteins

Beyond the preview

Go deeper on Enzystream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzystream.

Explore the full profile